Upload
others
View
5
Download
0
Embed Size (px)
Citation preview
HarnessingAdap-veNKCellsinCancerImmunotherapy
Karl-JohanMalmberg,
MD.PhD.Prof.
“Immunotherapyagainstcancerislikedryinganoceanwithanhairdryer”
Challenge
To decipher the cellular and molecular mechanisms underlying immune failure and exploit this knowledge to convert clinical non-responders to responders
Regula-onofNKcellfunc-onbykillercellimmunoglobulin-likereceptors(KIR)
MalmbergandLjunggren,NatureReviewsImmunology2007
Virus infection / Tumor transformation
Normal cell
Cancer/ Infected cell
Transformation/Infection
VariegatedKIRexpressionconfertoleranceandbroadspecifici-esinmissing-selfrecogni-on
Respondingcell
Haploidentical NK cell therapy - Preliminary results from a Phase I/II trial at the Karolinska Institute
NKcelltherapyacrossHLAbarriers–missingselfinthenewhost!
Kill
ProtocolDesign–RefractoryAMLorMDS
Escala-ngdoseoftotallymphoidirradia-on
(TLI)andaddi-onofCyclosporineA
3
3
3 Infusion of over night
IL-2 activated Haploidentical NK cells
6/16pa-entsreachingCRorPRbecomingeligibleforstemcell
transplanta-on
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
u ¤ è RAEB-2
u ¤ è MDS/AML
u ¤ ¢ è AML
u ¤ � ★ NK ✝
u � ★ ¢ è u CR/mCR/CRistart
u ¤ ✳ ✝ u mCR/PRstart
u � ★ NK ✝ u Stabledisease
u � ✝ � Responseend
✝ è Continuedresponse
✝
✝ ¤ SCT
u � ✝ ¢ DLI
✝ ★ Chemotherapy
u ✝ NK 2ndNK-treatment
✝ ✳ PTLDinCR
✝ ✝ Diseased
1year 2years 3years
Non-responder Responder0
20
40
60
80
100
Freq
uenc
y liv
e lin
- CD
34+ 0.0480
Reduc-onofCD34+blastcounts
Role for NK cells in the therapeutic effect?
NKcellmicro-chimerismatday7-14correlateswithclinicalresponses
Per
cent
of p
atie
nts
(%)
p=0.03
Non-responder Responder
Non-responder Responder0
10000
20000
30000
40000
GEO
M o
n liv
e lin
-C
D34
+CD
123+
CD
45R
A+ 0.0177
Immunoedi-ng–higherlevelsofHLAclassIonresidualblastsinresponders
Non-responder Responder0
200
400
600
800
Geo
M H
LA-E
on
live
lin-C
D34
+CD
123+
CD
45R
A+
0.0025
HLAclassI HLAE
Harnessing the power of adaptive NK cells
CyTOF:105
Horowitz et al., Science Transl. Med. 2013
NotallNKcellsareequal
CMVSCT
CD8 NK
Beziat et al., Blood, 2013b
Beziat et al., Blood, 2013a
Björklund et al., , Blood, 2010
Andersson et al., Blood, 2009
Björkström et al., Blood, 2010
Björkström et al., Blood, 2012
CNV
80
60
40
20
Blackrepertoires:CMV-nega-veindividualsn=48
Donor#164,C2C2CMV-posi-ve
Donor#59,C1C1CMV-posi-ve
PercentofN
Kcells
CMVisassociatedwithaclonal-likeexpansionofadap-veNKcells
BeziatV.etal.Blood2013
Expandingtumor-reac-veNKcells
CD2providessignal2inan-body-drivenadap-veNKcellresponses
Signal1Signal2
Expansionplagorms
Balancingnumbersandspecificity
Karolinska Institutet Per Ljungman Eva Hellström-Lindberg Petter Höglund Klas Kärre Sten Linnarsson Björn Önfelt Sören Lehman Björn Wahlin Hans-Gustaf Ljunggren Univ. of Minnesota Jeffrey Miller Sarah Cooley Univ. of Cambridge John Trowsdale James Traherne Stanford University Amir Horowitz Peter Parham
Oslo University Hospital (OUH) and UiO Johanna Olweus Arne Kolstad Eivind Hovig Andreas Brecht Harald Stenmark Kjetil Taskén Funding KI/SLL Theme Centers: Regenerative Medicine and IMTAC The Swedish Research Council The Swedish Cancer Foundation The Swedish Children's Cancer Foundation The Swedish Royal Society of Medicine Oslo University Hospital The Norwegian Cancer Society KG Jebsen Foundation
Malmberg group Karolinska Institutet Marie Schaffer Monika Enqvist Andreas Björklund Vivien Beziat (Paris) Lisa Liu Ebba Sohlberg Aline Pfefferle Oslo University Hospital Julie Hoel Merete Wiiger Vincent Yi Sheng Oei Eivind Ask-Hæggernes Jodie Peter Goodridge Kishan Chudasma Michelle Sætersmoen Trevor Clancy Benedikt Jakobs Axel Berg-Larsen
Acknowledgements